Market revenue in 2021 | USD 5,811.8 million |
Market revenue in 2030 | USD 22,870.9 million |
Growth rate | 16.4% (CAGR from 2021 to 2030) |
Largest segment | Breast cancer |
Fastest growing segment | Other Cancer |
Historical data covered | 2018 - 2020 |
Base year for estimation | 2021 |
Forecast period covered | 2022 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Blood Cancer, Breast Cancer, Urothelial Cancer & Bladder Cancer, Other Cancer |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to antibody drug conjugates market will help companies and investors design strategic landscapes.
breast cancer was the largest segment with a revenue share of 54.48% in 2021. Horizon Databook has segmented the Global antibody drug conjugates market based on blood cancer, breast cancer, urothelial cancer & bladder cancer, other cancer covering the revenue growth of each sub-segment from 2018 to 2030.
Horizon Databook provides a detailed overview of global-level data and insights on the Global antibody drug conjugates market , including forecasts for subscribers. This global databook contains high-level insights into Global antibody drug conjugates market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
No related regions found.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account